Shopping Cart
- Remove All
Your shopping cart is currently empty
NYX-2925, an orally active NMDAR (N-methyl-D-aspartate receptor) modulator, enhances activated Src levels and Src phosphorylation at GluN2A and GluN2B sites in the mPFC (medial prefrontal cortex), without affecting CAMKII (Ca2+/calmodulin-dependent protein kinase II) or exhibiting addictive or sedative/ataxic side effects. It is utilized in the study of various CNS (central nervous system) disorders mediated by NMDA receptors.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 25 mg | $2,270 | 10-14 weeks | |
| 50 mg | $2,980 | 10-14 weeks | |
| 100 mg | $4,000 | 10-14 weeks |
| Description | NYX-2925, an orally active NMDAR (N-methyl-D-aspartate receptor) modulator, enhances activated Src levels and Src phosphorylation at GluN2A and GluN2B sites in the mPFC (medial prefrontal cortex), without affecting CAMKII (Ca2+/calmodulin-dependent protein kinase II) or exhibiting addictive or sedative/ataxic side effects. It is utilized in the study of various CNS (central nervous system) disorders mediated by NMDA receptors. |
| Molecular Weight | 297.35 |
| Formula | C14H23N3O4 |
| Cas No. | 2012536-16-0 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.